Saracatinib and Alcohol Drinking

What is the purpose of this trial?

This project will evaluate the effect of an agent that indirectly modulates NMDA-R signaling without directly antagonizing NMDA-Rs on alcohol drinking. Primary Aim 1: To evaluate the effects of saracatinib (50 or 125 mg/day) versus placebo on alcohol craving. Primary hypothesis 1a: Saracatinib (50 or 125 mg/day) will reduce craving for alcohol after exposure to the priming drink of alcohol, and during the free-choice drinking period, when compared with placebo. Primary Aim 2: To evaluate the effects saracatinib (50 or 125 mg/day) versus placebo on alcohol drinking Primary hypothesis 1b: Saracatinib (50 or 125 mg/day) will reduce number of drinks consumed during the free-choice drinking period, when compared with placebo. Secondary Aim 1: To evaluate the effects of saracatinib (50 or 125 mg/day), versus placebo, on alcohol-induced stimulation and sedation during the ADP. Secondary Aim 2: To examine the tolerability of saracatinib (50 and 125 mg/day) in heavy drinkers. Exploratory Aims: To explore predictors of saracatinib response. The predictors have been selected based on findings from our earlier work and include behavioral outcomes like impulsivity, habit and deficiency in loss-avoidance learning and novel neuroimaging markers (collected by the CTNA Translational Core).


Participation Guidelines

Ages: 21 - 50 years

Gender: Both


National Institute on Alcohol Abuse and Alcoholism

Dates: 05/05/2017 - 02/01/2021

Last Updated: 05/31/2017

Study HIC#: 1601017043

Get Involved

For more information about this study, contact:
Nicholas Franco
203-974-7679
nicholas.franco@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image